Which has preferable earnings and valuation, INCY or ABBV?

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 3.82 $1.29B $7.08 13.89 AbbVie $61.16B 6.26 $4.23B $2.03 106.82

Is INCY or ABBV more profitable?

Incyte has a net margin of 26.71% compared to AbbVie's net margin of 5.79%. Incyte's return on equity of 26.66% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 26.71% 26.66% 19.77% AbbVie 5.79% -576.45% 13.39%

Does the media refer more to INCY or ABBV?

In the previous week, AbbVie had 42 more articles in the media than Incyte. MarketBeat recorded 64 mentions for AbbVie and 22 mentions for Incyte. AbbVie's average media sentiment score of 1.06 beat Incyte's score of 0.70 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 45 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor INCY or REGN?

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Incyte. MarketBeat recorded 36 mentions for Regeneron Pharmaceuticals and 22 mentions for Incyte. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Incyte's score of 0.70 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 32 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to INCY or ALNY?

In the previous week, Incyte and Incyte both had 22 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.93 beat Incyte's score of 0.70 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, INCY or BIIB?

Biogen has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 3.82 $1.29B $7.08 13.89 Biogen $9.89B 2.94 $1.29B $9.32 21.11

Is INCY or BIIB more profitable?

Incyte has a net margin of 26.71% compared to Biogen's net margin of 13.81%. Incyte's return on equity of 26.66% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 26.71% 26.66% 19.77% Biogen 13.81% 12.83% 8.01%

Does the media refer more to INCY or BIIB?

In the previous week, Biogen had 1 more articles in the media than Incyte. MarketBeat recorded 23 mentions for Biogen and 22 mentions for Incyte. Biogen's average media sentiment score of 0.78 beat Incyte's score of 0.70 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 12 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor INCY or UTHR?

In the previous week, Incyte and Incyte both had 22 articles in the media. Incyte's average media sentiment score of 0.70 beat United Therapeutics' score of 0.68 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 12 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 15 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Incyte (INCY) Competitors

$98.33 -0.66 (-0.67%)

Closing price 03:59 PM Eastern

Extended Trading

$99.09 +0.76 (+0.77%)

As of 04:04 PM Eastern

Compare

INCY vs. ABBV, REGN, ALNY, BIIB, and UTHR

Should you buy Incyte stock or one of its competitors? MarketBeat compares Incyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incyte include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.

How does Incyte compare to AbbVie?

Incyte (NASDAQ:INCY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Incyte currently has a consensus price target of $105.10, suggesting a potential upside of 6.88%. AbbVie has a consensus price target of $253.43, suggesting a potential upside of 16.87%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.82	$1.29B	$7.08	13.89
AbbVie	$61.16B	6.26	$4.23B	$2.03	106.82

Incyte has a net margin of 26.71% compared to AbbVie's net margin of 5.79%. Incyte's return on equity of 26.66% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
AbbVie	5.79%	-576.45%	13.39%

In the previous week, AbbVie had 42 more articles in the media than Incyte. MarketBeat recorded 64 mentions for AbbVie and 22 mentions for Incyte. AbbVie's average media sentiment score of 1.06 beat Incyte's score of 0.70 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	45 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

97.0% of Incyte shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AbbVie beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to Regeneron Pharmaceuticals?

Incyte (NASDAQ:INCY) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

In the previous week, Regeneron Pharmaceuticals had 14 more articles in the media than Incyte. MarketBeat recorded 36 mentions for Regeneron Pharmaceuticals and 22 mentions for Incyte. Regeneron Pharmaceuticals' average media sentiment score of 1.13 beat Incyte's score of 0.70 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	32 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

97.0% of Incyte shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Incyte presently has a consensus price target of $105.10, indicating a potential upside of 6.88%. Regeneron Pharmaceuticals has a consensus price target of $792.65, indicating a potential upside of 29.95%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.82	$1.29B	$7.08	13.89
Regeneron Pharmaceuticals	$14.92B	4.32	$4.50B	$41.04	14.86

Summary

Regeneron Pharmaceuticals beats Incyte on 12 of the 17 factors compared between the two stocks.

How does Incyte compare to Alnylam Pharmaceuticals?

Incyte (NASDAQ:INCY) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.82	$1.29B	$7.08	13.89
Alnylam Pharmaceuticals	$3.71B	10.01	$313.75M	$3.66	76.07

97.0% of Incyte shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Incyte has a net margin of 26.71% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

In the previous week, Incyte and Incyte both had 22 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.93 beat Incyte's score of 0.70 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	14 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte currently has a consensus target price of $105.10, indicating a potential upside of 6.88%. Alnylam Pharmaceuticals has a consensus target price of $463.13, indicating a potential upside of 66.36%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Summary

Incyte and Alnylam Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Incyte compare to Biogen?

Incyte (NASDAQ:INCY) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Biogen has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.82	$1.29B	$7.08	13.89
Biogen	$9.89B	2.94	$1.29B	$9.32	21.11

Incyte presently has a consensus price target of $105.10, indicating a potential upside of 6.88%. Biogen has a consensus price target of $217.37, indicating a potential upside of 10.47%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Biogen	1 Sell rating(s)	12 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.55

97.0% of Incyte shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incyte has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

In the previous week, Biogen had 1 more articles in the media than Incyte. MarketBeat recorded 23 mentions for Biogen and 22 mentions for Incyte. Biogen's average media sentiment score of 0.78 beat Incyte's score of 0.70 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	12 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte has a net margin of 26.71% compared to Biogen's net margin of 13.81%. Incyte's return on equity of 26.66% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Biogen	13.81%	12.83%	8.01%

Summary

Biogen beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to United Therapeutics?

Incyte (NASDAQ:INCY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Incyte currently has a consensus target price of $105.10, suggesting a potential upside of 6.88%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 15.27%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	3.82	$1.29B	$7.08	13.89
United Therapeutics	$3.18B	7.17	$1.33B	$27.09	19.84

Incyte has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, Incyte and Incyte both had 22 articles in the media. Incyte's average media sentiment score of 0.70 beat United Therapeutics' score of 0.68 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	12 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	15 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Incyte on 8 of the 15 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.64B	$3.39B	$6.41B	$12.60B
Dividend Yield	N/A	2.27%	2.67%	5.69%
P/E Ratio	13.89	19.40	24.46	24.45
Price / Sales	3.82	325.98	554.57	123.58
Price / Cash	16.14	125.35	43.94	55.48
Price / Book	3.74	8.18	10.71	6.59
Net Income	$1.29B	$23.89M	$3.57B	$337.29M
7 Day Performance	-8.81%	2.74%	0.66%	0.59%
1 Month Performance	3.30%	5.16%	3.66%	4.47%
1 Year Performance	44.03%	53.63%	28.47%	31.21%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	4.0198 of 5 stars	$98.33 -0.7%	$105.10 +6.9%	+43.9%	$19.64B	$5.14B	13.89	2,844	Analyst Forecast
ABBV AbbVie	4.663 of 5 stars	$223.00 -1.9%	$253.43 +13.6%	+19.3%	$401.47B	$61.16B	109.85	57,000	Positive News
REGN Regeneron Pharmaceuticals	4.8783 of 5 stars	$611.34 -3.8%	$792.65 +29.7%	+19.5%	$67.18B	$14.34B	14.90	15,410	Positive News
ALNY Alnylam Pharmaceuticals	4.5941 of 5 stars	$292.16 -3.6%	$463.13 +58.5%	-8.4%	$40.46B	$3.71B	79.83	2,770
BIIB Biogen	3.9159 of 5 stars	$192.62 -1.4%	$217.26 +12.8%	+57.0%	$28.84B	$9.89B	20.67	7,500	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors

INCY vs. ABBV, REGN, ALNY, BIIB, and UTHR

How does Incyte compare to AbbVie?

Summary

How does Incyte compare to Regeneron Pharmaceuticals?

Summary

How does Incyte compare to Alnylam Pharmaceuticals?

Summary

How does Incyte compare to Biogen?

Summary

How does Incyte compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY vs. The Competition

Incyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incyte (INCY) Competitors

INCY vs. ABBV, REGN, ALNY, BIIB, and UTHR

How does Incyte compare to AbbVie?

Which has more risk and volatility, INCY or ABBV?

Do analysts prefer INCY or ABBV?

Which has preferable earnings and valuation, INCY or ABBV?

Is INCY or ABBV more profitable?

Does the media refer more to INCY or ABBV?

Do insiders & institutionals have more ownership in INCY or ABBV?

Summary

How does Incyte compare to Regeneron Pharmaceuticals?

Is INCY or REGN more profitable?

Does the media favor INCY or REGN?

Do insiders and institutionals believe in INCY or REGN?

Which has more risk and volatility, INCY or REGN?

Do analysts recommend INCY or REGN?

Which has stronger earnings & valuation, INCY or REGN?

Summary

How does Incyte compare to Alnylam Pharmaceuticals?

Which has higher valuation and earnings, INCY or ALNY?

Do institutionals & insiders believe in INCY or ALNY?

Is INCY or ALNY more profitable?

Does the media refer more to INCY or ALNY?

Do analysts prefer INCY or ALNY?

Which has more risk and volatility, INCY or ALNY?

Summary

How does Incyte compare to Biogen?

Which has preferable earnings & valuation, INCY or BIIB?

Do analysts prefer INCY or BIIB?

Do institutionals and insiders believe in INCY or BIIB?

Which has more volatility and risk, INCY or BIIB?

Does the media refer more to INCY or BIIB?

Is INCY or BIIB more profitable?

Summary

How does Incyte compare to United Therapeutics?

Do insiders and institutionals have more ownership in INCY or UTHR?

Do analysts rate INCY or UTHR?

Which has higher earnings and valuation, INCY or UTHR?

Which has more risk & volatility, INCY or UTHR?

Does the media favor INCY or UTHR?

Is INCY or UTHR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCY vs. The Competition

Incyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools